Related Experiment Videos
Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders
M Abuzakouk1, C Feighery, J Jackson
1Department of Immunology, St. James's Hospital, Dublin, Ireland. mabuzakouk@stjames.ie
British Journal of Biomedical Science
|October 10, 2002
Summary
Anti-tumour necrosis factor-alpha (anti-TNF alpha) therapies offer a promising new treatment for inflammatory diseases like rheumatoid arthritis and Crohn's disease. These treatments show significant clinical benefits and a favorable safety profile, even for severe cases unresponsive to conventional therapies.
Area of Science:
- Immunology
- Rheumatology
- Gastroenterology
Background:
- Inflammatory diseases like rheumatoid arthritis and Crohn's disease pose significant challenges.
- Conventional therapies are often insufficient for severe or refractory cases.
Purpose of the Study:
- To review the development and clinical evidence of anti-tumour necrosis factor-alpha (anti-TNF alpha) therapies.
- To evaluate the efficacy and safety profile of anti-TNF alpha treatment.
Main Methods:
- Analysis of controlled randomized trials in rheumatoid arthritis and Crohn's disease.
- Review of existing literature on anti-TNF alpha therapy's clinical benefits and adverse effects.
Main Results:
- Anti-TNF alpha therapy demonstrates significant clinical benefit in severe active joint and intestinal disease.
- These benefits are often observed when conventional therapies fail.
- The treatment has shown a favorable safety profile and is generally well-tolerated.
Conclusions:
- Anti-tumour necrosis factor-alpha (anti-TNF alpha) treatment represents a significant advancement in managing inflammatory diseases.
- It offers a targeted approach with demonstrated efficacy and acceptable safety.
- Further consideration of its role in severe inflammatory conditions is warranted.